Smith Shellnut Wilson LLC ADV Sells 726 Shares of Gilead Sciences, Inc. (GILD)

Smith Shellnut Wilson LLC ADV decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.3% in the third quarter, Holdings Channel reports. The institutional investor owned 3,475 shares of the biopharmaceutical company’s stock after selling 726 shares during the quarter. Smith Shellnut Wilson LLC ADV’s holdings in Gilead Sciences were worth $282,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Keel Point LLC lifted its position in Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 12 shares during the last quarter. Paradigm Financial Advisors LLC lifted its position in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the last quarter. Princeton Portfolio Strategies Group LLC lifted its position in Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the last quarter. Auxier Asset Management lifted its position in Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 96 shares during the last quarter. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its position in Gilead Sciences by 1.6% in the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

In other news, Chairman John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the sale, the chairman now directly owns 3,046,766 shares of the company’s stock, valued at $254,587,766.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the sale, the executive vice president now directly owns 62,738 shares in the company, valued at $5,239,250.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 358,333 shares of company stock worth $28,066,908. Insiders own 1.30% of the company’s stock.

GILD has been the subject of several recent research reports. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a research report on Wednesday, January 17th. BMO Capital Markets lowered their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Maxim Group set a $94.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $86.56.

Shares of Gilead Sciences, Inc. (GILD) opened at $79.32 on Monday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54. The company has a market capitalization of $103,613.26, a price-to-earnings ratio of 9.29, a PEG ratio of -1.77 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the prior year, the firm posted $2.70 earnings per share. The company’s quarterly revenue was down 18.7% on a year-over-year basis. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.41 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.

COPYRIGHT VIOLATION WARNING: “Smith Shellnut Wilson LLC ADV Sells 726 Shares of Gilead Sciences, Inc. (GILD)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://sportsperspectives.com/2018/02/12/smith-shellnut-wilson-llc-adv-sells-726-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply